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Purpose: The study was aimed at evaluating the in vivo kinetics of silymarin tablets, a product with anti-
hepatotoxic and free radical scavenging activities.  
Methods: Silimarin
®
 (Amson Vaccines & Pharma Pvt Ltd) was used as the test product while another 
silymarin tablet brand, Silliver
®
 (Abbott Laboratories Pak Ltd) was the reference product. The tablets 
were administered to healthy male volunteers orally at a dose of 200 mg following an overnight fast 
according to a randomized cross-over design. Scheduled blood samples were collected, centrifuged and 
the plasma assayed using a sensitive and validated reversed phase high performance liquid 
chromatographic (RP-HPLC) method. Various pharmacokinetic parameters were calculated based on 
the non-compartmental model. 
Results: Non-significant difference (p < 0.05) was observed in the area under the curve (AUC) of the 
two brands with values of 10.8 ± 0.4 µg h/ml and 11.2 ± 0.7 µg h/ml, respectively. There was, however, 
a significant difference (p < 0.05) in the Cmax of the two brands. Other pharmacokinetic parameters 
evaluated did not show any statistical difference (p < 0.05) between the two products except for mean 
residence time  
Conclusion: The test product can be used as an alternative to the brand, Silliver
®
-Abbot (reference), 
only in conditions where maximum plasma concentration (Cmax) is not an important consideration. 
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INTRODUCTION 
 
Silymarin is an active extract of the seeds of 
Silybum marianum (milk thistle)
1
. A 
standardized extract of the seed contains 
approximately 70-80% of silymarin 
flavonolignans and 20-30% chemically 
undefined fraction, comprising mostly 























































                          
Figure 1: Structure of silymarin components. 
 
The main component of silymarin (Figure 1) 
is silybin or silibinin which is a mixture of 
diastereomers, namely, silybin A and silybin 
B. Isosilybin, dehydrosilybin, silychristin, 
silydianin are present in considerable 
amounts and a few flavonoids, such as 
taxifolin, are also present but in small 
amounts
2
. It is reported in literature that 
silymarin does not possess high 
bioavailability
3-8
. Silymarin absorption rate 
levels are between 20 and 50%
6
. In fact, this 
poor bioavailability could be attributed to 
degradation by gastric fluid
6
, poor enteral 
absorption
5,8
 or its poor water solubility
3,4,6,7
. 
Silymarin (an extract from Silybum marianum) 
contains silybin as a main component and, 
therefore, pharmacokinetic and bioavailability 
studies are always based on the 
determination of silybin in plasma
9-11
. 
Complex composition and the ever-increasing 
list of their putative active constituents in an 
herbal extract make bioavailability and 
pharmacokinetic studies problematic and task 
becomes even more difficult when the active 
constituents and synergistic interactions are 
not fully known
12
. Silymarin is one of the few 
herbal drugs whose active constituents have 
been sufficiently studied and on which 




Therefore, this work was designed and 
conducted to provide pharmacokinetic data 
on silymarin tablets that would facilitate the 
rational usage of this valuable medicinal 
agent, which is widely used in a variety of 




Subjects and Methods 
 
Healthy male volunteers ranging in age from 
22-40 years (23.1 ± 0.4 years), in weight from 
55-70 kg (62.5 ± 1.3 kg), and in height from 
165-180 cm (176.0 ± 1.8 cm) were enrolled 
according to the inclusion/exclusion criteria of 
Food and Drug Administration (FDA)
14
. 
Pharmacy Ethical Committee of the Faculty of 
Pharmacy and Alternative Medicine, the 
Islamia University of Bahawalpur, approved 
the study protocols for the human studies. 
Written informed consent was obtained from 
Silybin 
A,B = Diastereomers 
              A = β-H12; α-H13 
              B = α -H12; β-H13 
Isosilybin 
A,B = Diastereomers 
A = β-H12; α-H13 
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each volunteer who received an oral dose 
(200mg) of silymarin of both products 
according to a randomized cross-over design. 
A washout period of one week was allowed 
between the two treatments. The subjects 
were housed at the study centre throughout 
period of blood sampling. Approximately 3 ml 
aliquot of blood sample was collected pre-
dose (to serve as a control), and over a 
period of 12 h after sylimarin administration. 
The blood was centrifuged immediately and 
plasma was stored at -70 
0





Preparation of the mobile phase 
 
The mobile phase consisted of methanol and 
potassium dihydrogen phosphate buffer (20 
mM) in a ratio of 50:50 v/v with the pH of the 
buffer adjusted to 2.8 with phosphoric acid. It 
was filtered through a 0.45µm membrane 
filter before use. The flow rate was 1 ml/min 
at 30 
0





Preparation of stock solutions 
 
A stock solution of silymarin was prepared 
fresh by dissolving 50 mg drug in 50 ml of 
methanol to give a final concentration of 1 
mg/ml. Working solutions of silymarin were 
prepared in the mobile phase by appropriate 
dilution (2.5, 15, 30, 62.5, 125, 250 and 500 
µg/ml). All the solutions were stored at -20 
0
C, protected from light. 
 
Preparation of standard curve 
 
A standard curve was constructed to 
encompass anticipated range of plasma 
silymarin concentration found in healthy 
volunteers. The curve was prepared by 
spiking different samples of 1ml plasma each 
with 20 µl of one of the working solutions to 
produce calibration curve points equivalent to 
0.05, 0.3, 0.6, 1.25, 2.5, 5.0 and 10 µg/ml of 
silymarin. Aliquots of 100 µl were injected 
and spectra were taken in each case and the 
peak areas noted. The intra-day (within-run) 
and inter-day (between-run) accuracy and 
precision of the method were determined on 




An aliquot (100 µl) of acetate buffer (pH 5.6) 
and a 30 µl aliquot of β-glucuronidase Type 
HP-2 (Helix pomatia-Merck, Germany, 
1,27300 units/ml) were added to a 100µl 
aliquot of plasma sample and the mixtures 
were incubated at 37 C˚ for 2 h with 
periodical shaking. Then 200µl of borate 
buffer (pH 8.5) and 2.0 ml of diethyl ether 
were added to the mixture. The mixture was 
vortexed for 1 min and centrifuged at 3000 
rpm for 2 min. The organic phase was 
transferred into a clean sample test tube and 
evaporated under a gentle stream of nitrogen. 
The residue was reconstituted in a 130 µl 
aliquot of the mobile phase, vortexed for 30 
seconds and centrifuged for 1 min at 2500 
rpm, and then 100 µl of the solution was 
injected directly into the chromatographic 
system
15




Pharmacokinetic parameters were calculated 
using the pharmacokinetic software, Kinetica 
version 4.4 and MS Excel 2007. The rate and 
extent of absorption was measured by Cmax, 
Tmax and AUC0-∞ for both the reference and 
test products. Maximum concentration of 
silymarin in plasma (Cmax), time to reach peak 
plasma concentrations (Tmax) and area under 
the curve (AUC0-∞) were calculated by the 
trapezoidal rule. All other parameters - 
plasma half life (t1/2), elimination rate constant 
(Ke), volume of distribution (Vd), total body 
clearance (ClT) and mean residence time 
(MRT) - were determined with the aid of the 
software. 
 
Statistical analysis of data 
 
Paired t-test was applied for the 
determination of statistical difference between 
the values of the bioavailability and 
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pharmacokinetic parameters of the two 
brands of silymarin using Med. Calculator and 





The results of (mean ± SEM) plasma 
concentration versus time profiles for all the 
volunteers that received the treatments are 
plotted in Figure 2. Table 1 represents the 
values of bioavailability and other 
pharmacokinetic parameters. The values of 
AUC0-∞ for the two products (10.8 ± 0.4 and 
11.2 ± 0.7 µg h/ml for the test and reference, 
respectively) were not significantly different 
(P < 0.05). The maximum plasma 
concentration (Cmax) of the reference and test 
products were 2.9 ± 0.3 and 1.9 ± 0.1 µg/ml, 
respectively, and the difference was 
significant (p < 0.05). However, the Tmax of the 
reference and test products, which were 1.9 ± 
0.1 and 1.8 ± 0.1 h, respectively, are not 





























Figure 2: Mean plasma concentration vs time 
profile of reference product, Silliver
®
 (▲) and test 
product, Silimarin
®
 (○ ). 
 
Other pharmacokinetic parameters evaluated 
did not show any statistical difference (P < 
0.05) between the two products except mean 
residence time which was significantly 
different. They are (for reference and test 
products, respectively): elimination rate 
constant (Ke) - 0.3 ± 0.01 and 0.2 ± 0.02 h
-1 





); mean residence time (MRT) - 4.6 
± 0.2 and 6.1 ± 0.4 h; plasma half life (t1/2) - 
2.8 ± 0.1 and 3.536 ± 0.403 h; volume of 
distribution (Vd) - 1.2 ± 0.1 and 1.5 ± 0.2 
L/Kg; total body clearance (ClT) - 303.5 ± 44.1
 






Table 1: Comparative bioavailability and 





-Amson administered in an oral 












Cmax (µg/ml) 2.9 ± 0.3 1.9 ± 0.1
 s
 
Tmax  (h) 1.9 ± 0.1 1.8 ± 0.1
 ns
 
AUC (µg h/ml) 10.8 ± 0.4 11.2 ± 0.7
 ns
 
MRT (h) 4.6 ± 0.2 6.1 ± 0.4
 s
 





) 0.3 ± 0.01  0.2 ± 0.02
 ns
 
Vd (L/Kg) 1.2 ± 0.1 1.5 ± 0.2 
ns
 
Cl (ml/h/Kg) 303.5 ± 12.7 297.4 ± 18.1 
ns
 
* = pharmacokinetic parameter; s = Signifiant 





The task of in vivo evaluation of herbal 
medicines is difficult due to complex 
composition, ever-increasing list of their 
putative active constituents and specific 
analytical method
12,13
. Woo et al
17
 reported 
the value of AUC0-∞ as 22.75 ± 3.19 µg h/ml 
after the administration of silymarin capsule 
to rats at a dose of 140 mg/Kg. The 
difference between reported
17
 and present 
AUC values is due to differences in dose, 
dosage form, and experimental subjects.  
Therefore, it is evident that AUC0-∞ values in 
the present study a similar trend as in the 
previous studies. The variation in the values 
of Cmax of the two brands may be due to 
differences in the nature and source of the 
raw materials for the silymarin. It has been 
well documented that the proportion of active 
constituents in various silymarins depends 
largely on the source of Silybum marianum 
seeds. Moreover, various other factors - 
environmental, cultivation, drying and 
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processing procedures - can also influence 
the concentration of active ingredients. 
Silymarin is also extracted from the fruits of 
Silybum marianum instead of the seeds
17
. 
Silymarin extracted from the fruits of Silybum 
marianum may contain varied concentration 
of active principles which can lead to variation 
in Cmax. Another probable reason for the 
difference in Cmax values may be differences 
in the extraction procedures for the sylimarins 
used in the manufacture of the two products. 
Differences in formulation and processing 
variables could also have influenced the 
release of the drugs from the drug products, 
resulting in dissimilar Cmax values. The value 
of the bioavailability coefficient (F), calculated 
as 0.96 at 90% confidence interval, and the 
area under the curve (AUC) ratio should 





On the basis of the F (bioavailability 
coefficient) values and the AUC which fell in 
the range 80-125%, it can be said that 
Silimarin
®
-Amson can be used as a substitute 
for the better known brand, Silliver
®
-Abbott in 
healthy human subjects except in situations 
where the maximum plasma concentrations 
of the latter must be attained , e.g., in acute 
conditions such as acute pain. However, the 
test product should be suitable for use in 
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